Sector

Green capex plans of Power Grid, NTPC look too ambitious

While both companies forecast rapid addition of projects in the coming years, they don't match current capex trends. Investors should watch their return ratios and earnings

Concord Biotech IPO: A differentiated API portfolio to play the China+1 opportunity

The business warrants attention due to superior financials, barriers to entry, and significant market share for key molecules

Sugar mills in quandary after 2023-24 output decline forecast

India’s sugar output is expected to fall by 3.3 percent YoY in 2023-24, the second successive year of decline. It raises difficult questions for the industry and also the government 

What record plant availability at NTPC tells us about Indian power sector

Thermal power plant availability improved as electricity demand softened in June 2023 quarter

UPL: Near-term outlook clouded

Improvement in industry dynamics and continued efforts to reduce debt level will be key to growth

Coromandel International Q1FY24: Twinkled amidst challenging times

Emerging business segments hold good potential and are likely to be value-accretive.

Why Dr Lal PathLabs’ fat profit margins are bringing no cheer

Business volumes lagged expectations as patient footfalls are largely unchanged in Q1 FY24 from year ago period

Dr Reddy’s: US business momentum cannot be extrapolated

The key growth element missing for Dr Reddy’s is an India story. It aspires to improve its rank and increase maket share in the chronic portfolio in he country. At present, it is a work-in-progress

Cipla: Sailing well on the US pharma business front

The company’s chronic portfolio continues to gain strength and the US base business has moved to a new orbit. This is supportive for medium-term earnings growth, which makes us constructive on the business.

Sustained price hikes to aid profit margins of pharma companies

In the 12 months ending June 2023, price hikes contributed as much as half of the India pharma market growth

Yatharth Hospitals IPO: Wait for a more differentiated business model to emerge

The bulk of the business comes from the NCR region, which is a crowded market for hospitals. Hence, investors looking for long-term gains should wait

Midcap IT’s recovery optimism faces investor scrutiny

While frontline IT companies are uncertain about the near term outlook, Coforge, Persistent Systems and Mphasis sounded confident about sequential recovery

Rallis India’s results indicate tough times for agrochemical exporters 

While the export business is facing price erosion, delayed monsoon is feared to have weighed on product offtake in the June quarter

IndusInd Bank Q1 FY24: Can the stock rerate further?

The bank is adequately capitalised and has multiple levers to improve lending yield without compromising on asset quality

Rallis India: Long-term story in place despite near-term headwinds

We see an improvement in Rallis’ business in FY24-25 and view the current valuation as an opportunity for long-term gains.

Chart of the Day | Steady managed services market counters recession fears for Indian IT

Thanks to a healthy dosage of large deals, the managed services market hit a new high of $10 billion in the June quarter

LTIMindtree exudes cautious optimism

The company is ready to make the most of the multi-year technology spending opportunity

Indian pharma market records a blip, but stays the course for fresh rally

A delayed monsoon and reduced demand for acute products impacted the industry briefly, but analysts expect the sector to sustain double-digit growth figures for the year.

Chart of the Day | Thermal power plant utilisation levels steady, despite moderation in demand

Utilisation levels of thermal power plants exceeded 70 percent in April-June this year

IT firms’ generous payouts under threat as slowdown begins to bite

Amid the deceleration in growth rates, it will be tough for the companies to maintain the generous payouts of recent years.

KIMS: A structural growth story with well-oiled levers

KIMS is well-positioned to seize the growing demand for healthcare facilities in the country.

LTIMindtree stock enters big league, its operating metrics less so

LTIMindtree stock is the most expensive stock among the large vendors but its profit margins are significantly lower than TCS, Infosys

Pipeline Check: Here are the blockbuster drugs lined up by Indian drugmakers for US launch

Cipla is rolling out plans to launch a generic of Advair while Lupin has got approval for Spiriva

Untimely rain weighs on Coal India’s sales volumes 

Coal offtake increased by 5.4 percent in the June 2023 quarter, slower than the 10.6 percent expansion in the year ago period